Middle East Journal of Cancer

Scope & Guideline

Exploring innovative solutions in cancer studies.

Introduction

Explore the comprehensive scope of Middle East Journal of Cancer through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Middle East Journal of Cancer in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2008-6709
PublisherSHIRAZ UNIV MEDICAL SCIENCES
Support Open AccessNo
CountryIran
TypeJournal
Convergefrom 2014 to 2024
AbbreviationMIDDLE EAST J CANCER / Middle East J. Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNEMAZEE HOSPITAL, SHIRAZ 71934, IRAN

Aims and Scopes

The Middle East Journal of Cancer primarily focuses on advancing the understanding of cancer through a multidisciplinary approach that encompasses clinical, epidemiological, and molecular research. The journal aims to provide a platform for researchers, clinicians, and health professionals to share findings that can improve cancer diagnosis, treatment, and prevention, particularly within the Middle Eastern context.
  1. Clinical and Epidemiological Research:
    The journal publishes studies that investigate cancer incidence, risk factors, and outcomes, with a particular emphasis on populations in the Middle East. This includes retrospective cohort studies and case-control studies that provide insights into cancer trends and health disparities.
  2. Molecular and Cellular Oncology:
    Research focusing on the molecular mechanisms underlying cancer development and progression is a core area. The journal features studies on gene expression, signaling pathways, and the impact of various biomarkers on cancer prognosis and treatment responses.
  3. Innovative Treatment Modalities:
    The journal highlights clinical trials and studies investigating new treatment approaches, including chemotherapy, radiotherapy, immunotherapy, and targeted therapies. This includes reports on the efficacy and safety of novel drugs and treatment combinations.
  4. Public Health and Prevention:
    The journal emphasizes the importance of cancer prevention strategies and public health initiatives. This includes research on screening practices, health education, and the role of lifestyle factors in cancer risk.
  5. Case Reports and Clinical Practice:
    The journal includes detailed case reports that provide insights into unusual or complex cancer cases, contributing to the clinical knowledge base and informing practice.
The Middle East Journal of Cancer has been evolving, with several emerging trends and themes gaining momentum in recent publications. These trends reflect the latest advancements in cancer research and clinical practice.
  1. Integrative and Multimodal Treatment Approaches:
    Recent publications showcase a growing interest in integrative treatment strategies that combine traditional therapies with complementary approaches, such as dietary modifications and the use of natural products, indicating a shift towards holistic cancer management.
  2. Immunotherapy and Targeted Therapies:
    There is an increasing emphasis on studies related to immunotherapy and targeted therapies as a response to the growing importance of personalized medicine in oncology. This trend reflects the journal's commitment to covering cutting-edge treatment modalities.
  3. Cancer Survivorship and Quality of Life Studies:
    An emerging focus on cancer survivorship and the quality of life of patients post-treatment is evident. This includes research addressing psychological and social aspects of living with cancer, indicating a broader understanding of patient care.
  4. Advanced Diagnostic Techniques:
    The rising trend in the use of advanced diagnostic methods, including molecular profiling and imaging technologies, is prominent in recent publications. These studies aim to enhance early detection and improve treatment outcomes.
  5. Genomic and Proteomic Research:
    An increase in studies exploring the genomic and proteomic landscapes of various cancers is evident, highlighting the journal's focus on understanding cancer biology at a molecular level to inform treatment strategies.

Declining or Waning

While the Middle East Journal of Cancer has a broad and dynamic focus, some themes have seen a decline in prominence over recent years. The following areas appear to be waning based on publication trends.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable reduction in the number of publications focusing solely on traditional chemotherapy regimens without accompanying innovative approaches or combination therapies. This shift may reflect a broader trend towards personalized medicine and targeted therapies.
  2. Descriptive Epidemiological Studies:
    While epidemiological research remains important, there seems to be a decline in purely descriptive studies that do not incorporate newer methodologies or advanced statistical analyses. The journal may be moving towards more analytical approaches that provide deeper insights into cancer etiology.
  3. Studies on Less Common Cancers:
    Research focusing on rarer cancers appears to be less frequent. As the journal expands its focus on more prevalent cancers, studies on less common malignancies may receive less attention.

Similar Journals

JNCI-Journal of the National Cancer Institute

Transforming cancer treatment with trusted knowledge.
Publisher: OXFORD UNIV PRESS INCISSN: 0027-8874Frequency: 12 issues/year

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Southern African Journal of Gynaecological Oncology

Exploring regional challenges in gynecological cancer treatment.
Publisher: MEDPHARM PUBLICATIONS PTY LTDISSN: 2074-2835Frequency: 2 issues/year

The Southern African Journal of Gynaecological Oncology, published by MEDPHARM PUBLICATIONS PTY LTD, is a leading open-access journal that has been at the forefront of disseminating critical research in the field of gynecological oncology since its inception in 2009. With an ISSN of 2074-2835 and an E-ISSN of 2220-105X, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the nuanced complexities of women's health, particularly in the context of Southern Africa. The journal is dedicated to promoting innovative findings and clinical practices to enhance patient care in gynecological cancer treatment and prevention. Its open-access model ensures that high-quality, peer-reviewed research is readily available to a global audience, fostering collaboration and knowledge sharing within the academic community. As the journal continues to grow, it emphasizes the importance of addressing regional health challenges and advancing the discourse in gynecological oncology.

Journal of the Egyptian National Cancer Institute

Bridging gaps in cancer knowledge for a healthier tomorrow.
Publisher: SPRINGERISSN: 1110-0362Frequency: 1 issue/year

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

BULLETIN DU CANCER

Connecting research and practice to improve patient outcomes.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0007-4551Frequency: 12 issues/year

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

INTERNATIONAL JOURNAL OF CANCER

Exploring the frontiers of cancer science and treatment.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

Oncology Letters

Empowering Oncology with Groundbreaking Discoveries
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

INDIAN JOURNAL OF CANCER

Transforming Cancer Care Through Dedicated Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0019-509XFrequency: 4 issues/year

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

CANCER SCIENCE

Unlocking the mysteries of cancer through rigorous research.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Oncology Reviews

Empowering Oncology Insights for a Healthier Tomorrow
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Journal of Cancer

Empowering the global fight against cancer.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.